Stock Region Penny Picks
Welcome back to the Stock Region Penny Picks Watchlist!
Welcome back to the Stock Region Penny Picks Watchlist!
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: The information provided in this newsletter is for educational and informational purposes only. It does not constitute financial, investment, or trading advice. We are not licensed financial advisors. Always do your own research and consult with a professional before making any investment decisions. Trading stocks carries significant risk, and you could lose your entire investment.
The market never sleeps, and neither do we when it comes to hunting down the most fascinating moves on the ticker tape. We have seen some incredible catalysts dropping over the last 24 hours, ranging from life-changing biotech breakthroughs to massive corporate buybacks. Let’s dive right into the stories driving our watchlist today.
$BTAI - BioXcel Therapeutics
The News: BioXcel announced positive Phase 2 topline results from a Columbia University-led study of BXCL501 for treating opioid withdrawal.
Our Take: The opioid crisis has left a devastating mark on communities everywhere. Seeing a company make genuine, clinical strides toward a treatment for withdrawal is incredibly uplifting. Beyond the stock price, this is a win for humanity. If these results hold up in later phases, $BTAI could see massive momentum while doing incredible good.
$PDYN - Palladyne AI
The News: Reported Q4 and Full Year 2025 results, reiterating strong 2026 revenue guidance of $24 to $27 million.
Our Take: The AI sector can sometimes feel like a hype machine, but Palladyne is showing us real numbers. Reaffirming a hefty revenue target for 2026 tells us management is confident. We love seeing AI companies transition from flashy concepts to actual revenue-generating businesses.
$MDCX - Medicus Pharma
The News: Positive Phase 2 data observing 73% clinical clearance and 40% histological clearance at Day 57 for their 200μg cohort.
Our Take: A 73% clinical clearance rate is huge. Biotech stocks are famously volatile, but data like this cannot be ignored. The science is working, and investors usually flock to tangible clinical success. Keep a close eye on this one as it moves through the pipeline.
$MOBX - Mobix Labs
The News: Bagged new orders as Gulfstream aircraft production continues.
Our Take: Aerospace and luxury aviation bring in serious cash flow. Mobix Labs securing these orders shows they are a trusted partner in a highly regulated, high-margin industry. It is a solid, confidence-boosting update that points to steady operational growth.
$MTEK - Maris-Tech
The News: Strengthened their defense foothold with a first substantial order from a leading defense loitering munitions manufacturer.
Our Take: Global defense spending remains at a premium. Securing a substantial order in the loitering munitions space puts Maris-Tech right in the middle of modern defense tech. This is a strategic win that could open the door for plenty of follow-up contracts.
$PTRN - Pattern
The News: Reported record Q4 and Full Year 2025 financial results and announced a massive $100 million share repurchase program.
Our Take: Nothing screams “we believe in our company” quite like a $100 million stock buyback. Pattern knocked their earnings out of the park, and they are rewarding shareholders directly. This is the kind of aggressive, confident move that makes a stock incredibly attractive.
$YYGH - YY Group
The News: Projected an HKD 100 million revenue milestone in Hong Kong for 2026.
Our Take: Setting an aggressive milestone in a major financial hub shows immense ambition. Execution will be everything here, but if they can hit that HKD 100 million mark, YY Group will solidify its presence in the region. We are watching closely to see if their quarterly progress aligns with this bold projection.
Stay sharp, keep your emotions in check, and trade smart. We will see you next time!
Disclaimer: Stock Region and its administrators are not registered investment advisors. The content discussed in this newsletter reflects personal opinions and market observations, not actionable trading signals. All trading involves high risk. Past performance does not guarantee future results. Please manage your risk carefully and never invest money you cannot afford to lose.